The global Non-Hodgkin lymphoma treatment market is anticipated to grow at a significant CAGR during the forecast period. Various therapies such as biologic therapy, chemotherapy, and radiation therapy are used in the treatment of non-Hodgkin lymphoma conditions. Chemotherapy is considered to be the first line of treatment in Non-Hodgkin lymphoma treatment at the initial level. For advanced-stage Non-Hodgkin lymphoma conditions, chemotherapy is used along with radiation therapy. 

The recent rise in Non-Hodgkin types of lymphoma due to factors such as growth in the aging population across the globe has contributed to the growth of the market. The risk of Non-Hodgkin lymphoma in patients is high in every age group. However, it is found that around half of the patients at the time of their diagnosis are at 65. Moreover, increasing drug trails coupled with better diagnostic procedures will also drive the Non-Hodgkin lymphoma treatment market during the forecast period. However, the side effects associated with the Non-Hodgkin treatment which includes low platelets, low white blood cells, risk of developing various infections, and others, are anticipated to restrain the market of Non-Hodgkin lymphoma treatment during the forecast period. 

Segmental Outlook 

The global Non-Hodgkin lymphoma treatment market is segmented on the basis of the Cell type and therapy type. Based on cell type, the market is bifurcated into B-cell lymphoma and T-cell lymphoma. The treatment of B-cell Non-Hodgkin lymphoma is mainly based on the subtype and stage of the disease. In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell Non-Hodgkin lymphoma. Based on the therapy type, the market is sub-segmented into immunotherapy, chemotherapy, targeted therapy, radiation, and stem cell transplant.

Global Non-Hodgkin Lymphoma Treatment Market Share by Therapy Type, 2018 (%)

Radiation Therapy to Contribute a Significant Share

The radiation segment is anticipated to hold a significant market share in the Non-Hodgkin lymphoma treatment market owing to the increasing adoption rate of radiation therapy across the globe. Radiation therapy treatment can be either used alone or in combination with other treatments which is anticipated to rise the radiation therapy segment in the Non-Hodgkin lymphoma treatment market.

Regional Outlooks

The global Non-Hodgkin lymphoma treatment market is further segmented based on geography into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to hold the largest share in the Non-Hodgkin lymphoma treatment market during the forecast period owing to the increasing number of patients diagnosed with Non-Hodgkin lymphoma in the region. According to the American Cancer Society in 2020, around 77,240 people (including both adults and children) were anticipated to be diagnosed with Non-Hodgkin lymphoma cancer. In addition to this, Non-Hodgkin lymphoma is also considered as one of the most common cancers in the US as per the American Cancer Society, which accounts for about 4% of all cancer cases in the US.

Global Non-Hodgkin Lymphoma Treatment Market Growth by Region, 2019-2025

Asia-Pacific to Augment with Considerable Growth Rate in the Market

Asia-Pacific is anticipated to exhibit considerable growth rate in the Non-Hodgkin lymphoma treatment market. The key factor that drive the Non-Hodgkin lymphoma treatment market in the Asia-Pacific market includes the increasing availably of advanced healthcare facilities across the region. Government support and increasing awareness among the population will also significantly drive the market of Non-Hodgkin lymphoma treatment. 

Market Players Outlook

Some of the key players of the Non-Hodgkin lymphoma treatment market include AbbVie Inc., AstraZeneca PLC, Novartis International AG, Seattle Genetics, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Bayer AG, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market. 

Recent Activities

• In November 2019, Teva Pharmaceutical Industries Ltd. in partnership with Celltrion Healthcare Co., Ltd. and Celltrion, Inc. announced the availability of TRUXIMA (rituximab-abbs) in the form of an injection in the US. The TRUXIMA is used for the treatment of adult patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia conditions.
• In June 2018, Merck & Co., Inc., received the FDA clearance for the KEYTRUDA (pembrolizumab) which is used for the treatment of refractory or relapsed primary mediastinal large B-Cell lymphoma (PMBCL) conditions. It is the first anti-PD-1 therapy approved by the FDA for the treatment of PMBCL that is a type of Non-Hodgkin lymphoma condition.
• In October 2017, AstraZeneca PLC with its R&D center Acerta Pharma, LLC, announced the FDA approval of Calquence (acalabrutinib). Calquence is a kind of kinase inhibitor that is indicated for the treatment of mantle cell lymphoma (MCL) in adult patients who have already received at least one prior therapy. MCL is an aggressive B-cell Non-Hodgkin lymphoma that is harder to control.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Non-Hodgkin lymphoma treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.